Adefovir Dipivoxil Tablet
NDC Package 42794-003-08
Package Information
Adefovir Dipivoxil tablets are indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.For patients 12 to less than 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function. This formulation utilizes a tablet delivery system. Marketed by Sigmapharm Laboratories, Llc, this product is identified by NDC 42794-003 and is authorized under FDA application ANDA202051.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 42794 - Sigmapharm Laboratories, Llc
- 42794-003 - Adefovir Dipivoxil
- 42794-003-08 - 1 BOTTLE in 1 CARTON / 30 TABLET in 1 BOTTLE
- 42794-003 - Adefovir Dipivoxil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42794-003-08 identifies a specific commercial package of 1 bottle in 1 carton / 30 tablet in 1 bottle of Adefovir Dipivoxil, a human prescription drug labeled by Sigmapharm Laboratories, Llc. This tablet is formulated for oral use and contains adefovir dipivoxil as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sigmapharm Laboratories, Llc on September 03, 2013. The current certification is valid through December 31, 2027.
How is this Sigmapharm Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42794000308. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.